Horizon Discovery Group plc, a PerkinElmer company (“Horizon") drives the application of gene editing and gene modulation to support scientists on the path from research to therapy.
Horizon’s tools and services are used by many of the world’s foremost academic institutes, global pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to gain a greater understanding of gene function, identify genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver biotherapeutics, cellular and gene therapies for precision medicine.
With more than a decade of experience in the engineering of cell lines, Horizon offers an unmatched portfolio of innovative solutions based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines.
Horizon is headquartered in Cambridge, UK with offices in USA and Japan.